Oral adenoviral-based vaccines: historical perspective and future opportunity

@article{Tucker2008OralAV,
  title={Oral adenoviral-based vaccines: historical perspective and future opportunity},
  author={Sean N Tucker and Debora W. Tingley and Ciaran D. Scallan},
  journal={Expert Review of Vaccines},
  year={2008},
  volume={7},
  pages={25 - 31}
}
Adenoviral vaccines delivered orally have been used for decades to prevent respiratory illness, but are now being seriously explored again as a platform technology to make vaccines against a variety of pathogens. Years of use in military populations as a preventative measure for adenoviral infection have demonstrated the safety of oral administration of adenovirus. The advantages of using this approach as a platform technology for vaccines include rapid development and distribution, as well as… 
View on Taylor & Francis
ncbi.nlm.nih.gov
44 Citations
Background Citations
16
Methods Citations
1
Results Citations
1

44 Citations

Citation Type

Citation Type

Antigen delivery systems for veterinary vaccine development
Production of adenovirus vectors and their use as a delivery system for influenza vaccines
TLDR
Ad-vector technology and the current progress in the development of Ad-based influenza vaccines for pandemic preparedness are under development to meet global vaccine demand.
Recent progress in mucosal vaccine development: potential and limitations
  • N. Lycke
  • Medicine, Biology
    Nature Reviews Immunology
  • 2012
TLDR
The expanding knowledge and strategies used in the development of mucosal vaccines are discussed, and great expectations for new mucosalvaccines lie ahead.
A single oral immunization with a replication-competent adenovirus-vectored vaccine protects mice from influenza respiratory infection
TLDR
Oral vaccination of mice with MAV-1 vectors expressing the full length or the “headless” hemagglutinin (HA) of influenza showed that while the headless HA vector did not generate a significant humoral or cellular immune response to influenza, a single oral immunisation with the full-length HA vaccine generated influenza-specific and neutralizing antibodies and completely protected the mice against clinical signs and viral replication.
Enhancing Oral Vaccine Potency by Targeting Intestinal M Cells
TLDR
The challenges associated with current oral vaccine delivery systems are reviewed and strategies that might potentially target mouse and human intestinal M cells are discussed, which might enhance the entry of antigens, initiating the immune response and consequently leading to protection against mucosal pathogens.
Oral immunization: an update
TLDR
Improvements in antigen-delivery systems, the development of adjuvants that are safe for mucosal application in humans, use of live-attenuated vaccines and microbial vectors, and production of certain vaccines in plant expression systems are likely to contribute to the broader use of oral vaccines in the future.
Oral Vaccination: Attenuated and Gene-Based
TLDR
This chapter reviews the history of oral vaccines, both approved and vaccines in early stages of development, and several oral platform approaches are under investigation that might expand the available pool of vaccines.
Oral Vaccination with Replication-Competent Adenovirus in Mice Reveals Dissemination of the Viral Vaccine beyond the Gastrointestinal Tract
TLDR
It is shown that MAV-1 oral administration provides protection that recapitulates the protection against homologous respiratory challenge observed with adenovirus 4 and 7 vaccines and better protected against a respiratory challenge than inactivated vaccines.
Pulmonary vaccine delivery: a realistic approach?
TLDR
The current status of pulmonary vaccination, the potential advantages of pulmonary vaccine delivery, the hurdles to overcome in the future, and the overall perspectives of this vaccination strategy are described.
An Adenovirus-Based Vaccine with a Double-Stranded RNA Adjuvant Protects Mice and Ferrets against H5N1 Avian Influenza in Oral Delivery Models
TLDR
Protection against avian influenza virus challenge using a chimeric adenovirus vector expressing hemagglutinin and a double-stranded RNA adjuvant and the ability to circumvent preexisting vector immunity is assessed.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 69 REFERENCES
Adenovirus vector-based vaccines for human immunodeficiency virus type 1.
TLDR
Progress is described in the development of rAd vector-based vaccines with a focus on human immunodeficiency virus type 1, and the inherent immunogenicity of these vectors is a desirable feature for vaccine development.
Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors.
TLDR
Comparative immunization experiments have demonstrated that replication-incompetent adenovirus vectors are an effective means for eliciting cytotoxic T-lymphocyte immune responses against HIV-1 antigens, and these immune responses effectively control viremia in nonhuman primates following challenge with simian AIDS viruses.
Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41.
Oral Vaccination of Mice with Adenoviral Vectors Is Not Impaired by Preexisting Immunity to the Vaccine Carrier
TLDR
Serum rabies virus-neutralizing antibody titers sufficed to protect neonatally vaccinated mice against a subsequent challenge with rabiesirus.
Mucosally Delivered E1-Deleted Adenoviral Vaccine Carriers Induce Transgene Product-Specific Antibody Responses in Neonatal Mice 1
TLDR
Serum rabies virus neutralizing Ab titers sufficed to protect neonatally vaccinated mice against a subsequent challenge with rabiesirus.
Long–term hepatic adenovirus–mediated gene expression in mice following CTLA4Ig administration
TLDR
It is demonstrated that systemic coadministration of recombinant adenovirus with soluble CTLA4lg, which is known to block co–stimulatory signals between T cells and antigen presenting cells, leads to persistentAdenoviral gene expression in mice without long–term immunosuppression.
Communicability of enteric live adenovirus type 4 vaccine in families.
Use of inactivated adenovirus vaccines prepared in monkey kidney tissue cultures was discontinued because of the inability to exclude, with certainty, genetic constituents of an unwanted simian virus…
Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus.
  • M. Lubeck, A. Davis, P. Hung
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 1989
TLDR
It is demonstrated here that chimpanzees are susceptible to enteric infection by human adenoviruses type 7 (Ad7) and type 4 (Ad4) following oral administration of live virus, and the feasibility of using orally administered recombinant adenOViruses as a general approach to vaccination is demonstrated.
Immune responses to adenovirus and adeno-associated virus in humans
TLDR
Significant heterogeneity in pre-existing immunity to Ad5 and AAV2 in human populations is demonstrated and the impact of these findings on outcome following gene therapy will require further study.
Biological safety concepts of genetically modified live bacterial vaccines.
...
1
2
3
4
5
...